CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced that Michael J. Pellini, M.D., president and chief executive officer, will present an overview of the company at the Worldwide Innovative Networking (WIN) 2012 Symposium being held June 28-29 in Paris, France. The WIN Consortium in personalized cancer medicine is initiating a clinical trial that uses FoundationOne™, a genomic profile for cancer developed by Foundation Medicine. Details of the trial will be highlighted at the Symposium.
“FoundationOne will allow physicians participating in this trial to test for alterations in clinically-relevant genes known to be associated with human cancer and match these alterations with appropriate targeted therapies or clinical trials,” said Dr. John Mendelsohn, chairman of WIN Consortium. “WIN and Foundation Medicine are both dedicated to enabling the best treatment possible with the therapies most likely to be effective against an individual patient’s cancer. We believe this trial is an important step in that direction.”
About WIN Consortium and WIN 2012 Symposium
WIN Consortium is a network of 22 academic institutions and industries across the globe, initiated by the Cancer Institute Gustave Roussy (IGR), France and University of Texas MD Anderson Cancer Center, USA (MDACC) and focused on international biomarker-driven therapeutic clinical trials. Foundation Medicine joined the consortium in March 2012.
The WIN 2012 Symposium is dedicated to the efficacy of personalized cancer therapeutics through an open exchange format with investigators from academic institutions and the biopharma industry.
Foundation Medicine and the clinical trial will be discussed on June 28th during Session 2 of the WIN 2012 Symposium at the Palais des Congrès in Porte Maillot, Paris, France:
|
Date & Time: |
Thursday, June 28, 11:20 CET | ||
|
Title: |
Utilizing next generation sequencing (NGS) in clinical oncology | ||
|
Presenter: |
Michael Pellini, President and Chief Executive Officer, Foundation Medicine | ||
|
Date & Time: |
Thursday, June 28, 11:40 CET | ||
|
Title: |
WINTHER–WIN therapeutics clinical trial and panel discussion |
||
|
Presenters: |
Razelle Kurzrock, FACP, Chair, Phase I Program, University of Texas MD Anderson Cancer Center and Josep Tabernero, Head Medical Oncology Division, Vall d‘Hebron, Spain | ||
|
Panel Discussion: |
Jack J. Lee, Biostatistics, University of Texas MD Anderson Cancer Center, USA | ||
| Amir Onn, SOP, Medical Oncology Division, Chaim Sheba Medical Center, Israel | |||
| Eitan Rubin, Bioinformatics, Ben Gurion University of Negev, Israel | |||
| Gary Palmer, Foundation Medicine, Cambridge, USA | |||
|
Vladimir Lazar, Chief Operating Officer, WIN Consortium and Head, Genomic Centre, Cancer Institute Gustave Roussy, France |
|||
| Philippe Vielh, Pathologist, Cancer Institute Gustave Roussy, France | |||
About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s initial clinical product, FoundationOne™, is a fully informative genomic profile to identify a patient’s individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.foundationmedicine.com.